Nonalcoholic steatohepatitis and the cardiometabolic syndrome.
Nonalcoholic steatohepatitis and the cardiometabolic syndrome.
复制标题
DOI：
10.1111/j.0197-3118.2006.05523.x
复制
发表时间：
2006-01-01
期刊：
影响因子：
--
通讯作者：
Ibdah, Jamal A
中科院分区：
文献类型：
--
作者：
Abdeen, Mohammad Bosem;Chowdhury, Nazif A;Ibdah, Jamal A
非酒精性脂肪肝（NAFLD）现在被认为是美国最常见的肝脏疾病，涉及一系列进行性组织病理学变化。与 NAFLD 相关的常见危险因素包括肥胖、糖尿病和高脂血症。尽管大多数 NAFLD 患者患有单纯性肝脂肪变性，但仍有相当一部分患者发展为非酒精性脂肪性肝炎，并可能进展为纤维化、肝硬化或终末期肝病。越来越多的证据表明，NAFLD 是心脏代谢综合征患者的一个常见特征，心脏代谢综合征是一系列代谢、心血管、肾脏和炎症异常的疾病，其中胰岛素抵抗被认为在终末器官发病机制中发挥着关键作用。 NAFLD 通常是在常规实验室检查中发现肝脏化学结果异常后诊断出来的。目前尚无任何疗法被证明可有效治疗 NAFLD/非酒精性脂肪性肝炎。专家意见强调运动、肥胖和超重个体减肥、高脂血症治疗和血糖控制的重要性。
Nonalcoholic fatty liver disease (NAFLD) is now considered to be the most common liver disease in the United States and involves a spectrum of progressive histopathologic changes. Common risk factors associated with NAFLD include obesity, diabetes, and hyperlipidemia. Although most patients with NAFLD have simple hepatic steatosis, a significant number develop nonalcoholic steatohepatitis, which may progress to fibrosis, cirrhosis, or end-stage liver disease. There is increasing evidence that NAFLD is a common feature in patients with the cardiometabolic syndrome, a onstellation of metabolic, cardiovascular, renal, and inflammatory abnormalities in which insulin resistance is thought to play a key role in end-organ pathogenesis. NAFLD is usually diagnosed after abnormal liver chemistry results are found during routine laboratory testing. No therapy has been proven effective for treating NAFLD/nonalcoholic steatohepatitis. Expert opinion emphasizes the importance of exercise, weight loss in obese and overweight individuals, treatment of hyperlipidemia, and glucose control.